P Wahlqvist

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi request reprint Validity of a Work Productivity and Activity Impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD)--results from a cross-sectional study
    Peter Wahlqvist
    Health Economics AstraZeneca R and D, Molndal, Sweden
    Value Health 5:106-13. 2002
  2. pmc Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France
    Stanislas Bruley Des Varannes
    Institut des Maladies de L appareil Digestif, University Hospital CHU Hôtel Dieu, Place A Ricordeau, Nantes Cedex, 44093, France
    BMC Gastroenterol 13:39. 2013
  3. pmc The impact of illness in patients with moderate to severe gastro-esophageal reflux disease
    Samer El-Dika
    Division of Gastroenterology, Veterans Affairs Medical Center, Salem, Virginia, USA
    BMC Gastroenterol 5:23. 2005
  4. doi request reprint Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort
    P Wahlqvist
    Health Economics and Outcomes Research, AstraZeneca R and D Molndal, Molndal, Sweden
    Aliment Pharmacol Ther 27:960-70. 2008
  5. ncbi request reprint The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD): responsiveness to change and English language validation
    Peter Wahlqvist
    AstraZeneca R and D, Molndal, Sweden
    Pharmacoeconomics 25:385-96. 2007
  6. ncbi request reprint Systematic review: the impact of gastro-oesophageal reflux disease on work productivity
    P Wahlqvist
    AstraZeneca R and D Molndal, Molndal, Sweden
    Aliment Pharmacol Ther 24:259-72. 2006
  7. ncbi request reprint Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK
    Peter Wahlqvist
    AstraZeneca R and D Molndal, Sweden
    Pharmacoeconomics 20:279-87. 2002
  8. ncbi request reprint Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies
    Peter Wahlqvist
    AstraZeneca R and D Molndal, Sweden
    Pharmacoeconomics 20:267-77. 2002
  9. doi request reprint The burden of disrupting gastro-oesophageal reflux disease: a database study in US and European cohorts
    Samira Toghanian
    AstraZeneca R and D, Molndal, Sweden
    Clin Drug Investig 30:167-78. 2010
  10. doi request reprint Objective measurement of work absence and on-the-job productivity: a case-control study of US employees with and without gastroesophageal reflux disease
    Peter Wahlqvist
    AstraZeneca R and D Molndal, Molndal, Sweden
    J Occup Environ Med 50:25-31. 2008

Detail Information

Publications12

  1. ncbi request reprint Validity of a Work Productivity and Activity Impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD)--results from a cross-sectional study
    Peter Wahlqvist
    Health Economics AstraZeneca R and D, Molndal, Sweden
    Value Health 5:106-13. 2002
    ..To validate a Work Productivity and Activity Impairment questionnaire (WPAI-GERD) developed to measure lost productivity due to symptoms of gastro-esophageal reflux disease (GERD)...
  2. pmc Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France
    Stanislas Bruley Des Varannes
    Institut des Maladies de L appareil Digestif, University Hospital CHU Hôtel Dieu, Place A Ricordeau, Nantes Cedex, 44093, France
    BMC Gastroenterol 13:39. 2013
    ..This observational study aimed to provide information on symptoms, HRQL, resource usage, costs and treatment pathways associated with partial response to PPI therapy in French patients with GERD...
  3. pmc The impact of illness in patients with moderate to severe gastro-esophageal reflux disease
    Samer El-Dika
    Division of Gastroenterology, Veterans Affairs Medical Center, Salem, Virginia, USA
    BMC Gastroenterol 5:23. 2005
    ..Gastro-esophageal reflux disease (GERD) is a common disease. It impairs health related quality of life (HRQL). However, the impact on utility scores and work productivity in patients with moderate to severe GERD is not well known...
  4. doi request reprint Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort
    P Wahlqvist
    Health Economics and Outcomes Research, AstraZeneca R and D Molndal, Molndal, Sweden
    Aliment Pharmacol Ther 27:960-70. 2008
    ..Analysis of the burden of gastro-oesophageal reflux disease (GERD) in relation to the severity and frequency of symptoms is essential to identify individuals and groups in whom targeted management is justified...
  5. ncbi request reprint The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD): responsiveness to change and English language validation
    Peter Wahlqvist
    AstraZeneca R and D, Molndal, Sweden
    Pharmacoeconomics 25:385-96. 2007
    ..A validated productivity questionnaire, the Work Productivity and Activity Impairment questionnaire for Gastroesophageal Reflux Disease (WPAI-GERD), exists for Swedish patients with GERD...
  6. ncbi request reprint Systematic review: the impact of gastro-oesophageal reflux disease on work productivity
    P Wahlqvist
    AstraZeneca R and D Molndal, Molndal, Sweden
    Aliment Pharmacol Ther 24:259-72. 2006
    ..Gastro-oesophageal reflux disease has wide-ranging effects on patients' lives...
  7. ncbi request reprint Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK
    Peter Wahlqvist
    AstraZeneca R and D Molndal, Sweden
    Pharmacoeconomics 20:279-87. 2002
    ..Clinical studies have demonstrated that esomeprazole is superior to omeprazole for the acute treatment of reflux oesophagitis...
  8. ncbi request reprint Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies
    Peter Wahlqvist
    AstraZeneca R and D Molndal, Sweden
    Pharmacoeconomics 20:267-77. 2002
    ....
  9. doi request reprint The burden of disrupting gastro-oesophageal reflux disease: a database study in US and European cohorts
    Samira Toghanian
    AstraZeneca R and D, Molndal, Sweden
    Clin Drug Investig 30:167-78. 2010
    ..Recent data indicate that among patients with gastro-oesophageal reflux disease (GORD) there is a subgroup with a higher disrupting burden of illness in terms of symptom frequency and overall impact...
  10. doi request reprint Objective measurement of work absence and on-the-job productivity: a case-control study of US employees with and without gastroesophageal reflux disease
    Peter Wahlqvist
    AstraZeneca R and D Molndal, Molndal, Sweden
    J Occup Environ Med 50:25-31. 2008
    ..To establish an association between gastroesophageal reflux disease (GERD) and increased work absence, as well as reduced productivity while at work, by using objective productivity measurements...
  11. ncbi request reprint Employers need to have a wider horizon than drug costs alone when considering the implementation of health care intervention programs
    Peter Wahlqvist
    J Manag Care Pharm 12:581-2; author reply 582-3. 2006
  12. ncbi request reprint A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective
    Manishi Prasad
    MEDTAP International, Inc, Bethesda, Maryland, USA
    Pharmacoeconomics 22:225-44. 2004
    ..Health-related productivity has been increasingly recognised as an important component of the burden of illness associated with a given disease; without it, one cannot reliably assess this burden...